ES2180646T3 - Formulaciones liquidas orales de alendronato. - Google Patents
Formulaciones liquidas orales de alendronato.Info
- Publication number
- ES2180646T3 ES2180646T3 ES95924570T ES95924570T ES2180646T3 ES 2180646 T3 ES2180646 T3 ES 2180646T3 ES 95924570 T ES95924570 T ES 95924570T ES 95924570 T ES95924570 T ES 95924570T ES 2180646 T3 ES2180646 T3 ES 2180646T3
- Authority
- ES
- Spain
- Prior art keywords
- alendronate
- oral liquid
- liquid formulations
- swallowing
- syrup
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SE MUESTRA UN PROTOCOLO TERAPEUTICO PARA TRATAR Y PREVENIR LA PERDIDA OSEA EN PACIENTES QUE TIENEN DIFICULTAD DE ABSORCION MEDIANTE LA ADMINISTRACION DE UNA FORMULA LIQUIDA DE ALENDRONATO QUE PUEDE SER FACILMENTE ABSORBIBLE. TAMBIEN SE DESCRIBEN FORMULAS DE DOSIFICACION FARMACEUTICA EN FORMA DE SIROPE, SOLUCION ACUOSA, SOLUCION FORMADA DE POLVO RECONSTITUIDO, DE ALENDRONATO, PARA DESARROLLAR EL METODO TERAPEUTICO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/245,289 US5462932A (en) | 1994-05-17 | 1994-05-17 | Oral liquid alendronate formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2180646T3 true ES2180646T3 (es) | 2003-02-16 |
Family
ID=22926074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95924570T Expired - Lifetime ES2180646T3 (es) | 1994-05-17 | 1995-05-12 | Formulaciones liquidas orales de alendronato. |
Country Status (34)
Country | Link |
---|---|
US (1) | US5462932A (es) |
EP (1) | EP0759757B1 (es) |
JP (1) | JP4111536B2 (es) |
KR (1) | KR100372966B1 (es) |
CN (1) | CN1079672C (es) |
AT (1) | ATE222495T1 (es) |
AU (1) | AU691634B2 (es) |
CA (1) | CA2190148C (es) |
CO (1) | CO4600739A1 (es) |
CY (1) | CY2336B1 (es) |
CZ (1) | CZ285860B6 (es) |
DE (1) | DE69527842T2 (es) |
DK (1) | DK0759757T3 (es) |
DZ (1) | DZ1884A1 (es) |
ES (1) | ES2180646T3 (es) |
FI (1) | FI118296B (es) |
HK (1) | HK1009245A1 (es) |
HR (1) | HRP950293B1 (es) |
HU (1) | HU220626B1 (es) |
IL (1) | IL113651A (es) |
MX (1) | MX9605660A (es) |
MY (1) | MY112285A (es) |
NO (1) | NO310179B1 (es) |
NZ (1) | NZ289231A (es) |
PL (1) | PL179634B1 (es) |
PT (1) | PT759757E (es) |
RU (1) | RU2176507C2 (es) |
SI (1) | SI0759757T1 (es) |
SK (1) | SK281098B6 (es) |
TW (1) | TW402501B (es) |
UA (1) | UA29505C2 (es) |
WO (1) | WO1995031203A1 (es) |
YU (1) | YU49354B (es) |
ZA (1) | ZA953960B (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780455A (en) * | 1994-08-24 | 1998-07-14 | Merck & Co., Inc. | Intravenous alendronate formulations |
KR19980702210A (ko) * | 1995-02-17 | 1998-07-15 | 폴락 돈나 엘 | 비척추골 골절의 위험률을 감소시키는 방법 |
CA2219354A1 (en) * | 1995-05-12 | 1996-11-14 | Merck & Co., Inc. | Prevention of tooth loss by the administration of alendronate or its salts |
IL118422A0 (en) * | 1995-06-02 | 1996-09-12 | Merck & Co Inc | Use of alendronate for the prevention of osteoporosis |
US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
JPH11506750A (ja) * | 1995-06-06 | 1999-06-15 | メルク エンド カンパニー インコーポレーテッド | 慢性関節リウマチに係わる骨欠損に対するビスホスホネート療法 |
IL120270A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis |
US6100301A (en) * | 1996-02-28 | 2000-08-08 | Pfizer Inc | Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists |
PL332496A1 (en) * | 1996-10-04 | 1999-09-13 | Merck & Co Inc | Liquid alendronate preparations |
US6376477B2 (en) | 1996-11-25 | 2002-04-23 | Merck & Co., Inc. | Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism |
US6376476B1 (en) * | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
US6080779A (en) * | 1996-12-13 | 2000-06-27 | Osteoscreen, Inc. | Compositions and methods for stimulating bone growth |
FI104901B (fi) | 1997-10-20 | 2000-04-28 | Leiras Oy | Uudet metyleenibisfosfonihappojohdannaiset |
GB9802617D0 (en) * | 1998-02-07 | 1998-04-01 | Knoll Ag | Pharmaceutical formulation |
US6331533B1 (en) | 1998-11-16 | 2001-12-18 | Merck & Co., Inc. | Method for inhibiting dental resorptive lesions |
US6194469B1 (en) * | 1998-12-11 | 2001-02-27 | Board Of Trustees Operating Michigan State Univeristy | Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids |
CN1372468A (zh) * | 1999-06-02 | 2002-10-02 | 宝洁公司 | 羟乙磷酸二钠口服制剂 |
US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
US6468559B1 (en) | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
US7008640B2 (en) * | 2000-07-17 | 2006-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral use with improved absorption |
WO2002058708A1 (en) * | 2001-01-23 | 2002-08-01 | Gador S.A. | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
US7537622B2 (en) * | 2001-10-10 | 2009-05-26 | Fmi Newcoal, Inc. | Process for drying coal |
US8197561B2 (en) | 2001-10-10 | 2012-06-12 | River Basin Energy, Inc. | Process for drying coal |
US7695535B2 (en) | 2001-10-10 | 2010-04-13 | River Basin Energy, Inc. | Process for in-situ passivation of partially-dried coal |
CA2468687A1 (en) * | 2001-12-13 | 2003-06-26 | Merck & Co., Inc. | Liquid bisphosphonate formulations for bone disorders |
MXPA04006027A (es) * | 2001-12-21 | 2004-09-27 | Procter & Gamble | Metodo para el tratamiento de trastornos de los huesos. |
EP1880744B1 (en) * | 2002-05-10 | 2015-01-21 | F.Hoffmann-La Roche Ag | Bisphosphonic acids for the treatment and prevention of osteoporosis |
ITTO20020406A1 (it) * | 2002-05-13 | 2003-11-13 | Chiesi Farma Spa | Formulazioni di bisfosfonati ad uso iniettabile. |
US7041309B2 (en) * | 2002-06-13 | 2006-05-09 | Neuropro Technologies, Inc. | Spinal fusion using an HMG-CoA reductase inhibitor |
GR1004331B (el) * | 2002-10-07 | 2003-09-05 | Verisfield (Uk) Ltd | Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος |
ES2530791T3 (es) * | 2002-12-20 | 2015-03-05 | Hoffmann La Roche | Formulación de ibandronato de altas dosis |
US20050101605A1 (en) * | 2003-11-07 | 2005-05-12 | Ahmed Salah U. | Oral liquid formulations of methotrexate |
US7645460B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
US20080287400A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US20080286359A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
DE602005022578D1 (de) * | 2004-05-24 | 2010-09-09 | Warner Chilcott Co Llc | Enterische feste orale dosierform eines bisphosphonats mit einem chelate |
US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
EP1761270A1 (en) * | 2004-06-23 | 2007-03-14 | Merck & Co., Inc. | Estrogen receptor modulators |
EP1796683A1 (en) * | 2004-07-15 | 2007-06-20 | Nanobac Life Sciences | Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses |
WO2006020009A1 (en) * | 2004-07-23 | 2006-02-23 | The Procter & Gamble Company | Solid oral dosage form of a bisphosphonate containing a chelating agent |
US7687482B2 (en) * | 2006-03-17 | 2010-03-30 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods |
EP1802641B8 (en) * | 2004-10-08 | 2012-03-07 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
WO2008128056A1 (en) * | 2004-10-08 | 2008-10-23 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps |
US20060134190A1 (en) * | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
ES2361333T3 (es) * | 2006-09-04 | 2011-06-16 | Gador S.A. | Composición líquida para la prevención y/o el tratamiento de diferentes enfermedades metabólicas óseas, usos de la misma, y procedimiento para la preparación de la misma. |
MX2009001271A (es) * | 2006-11-21 | 2009-02-11 | Teikoku Pharma Usa Inc | Formulaciones inhalantes de bisfosfonato y metodos para el uso de las mismas. |
US8974801B2 (en) * | 2006-12-21 | 2015-03-10 | Amphastar Pharmaceuticals Inc. | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
US20090170815A1 (en) * | 2007-12-28 | 2009-07-02 | Roxane Laboratories Incorporated. | Alendronate oral liquid formulations |
CA2711413A1 (en) * | 2008-02-05 | 2009-08-13 | Actavis Group Ptc Ehf | Alendronate formulations, method of making and method of use thereof |
US20100034752A1 (en) * | 2008-08-11 | 2010-02-11 | Toru Hibi | Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same |
US8956426B2 (en) | 2010-04-20 | 2015-02-17 | River Basin Energy, Inc. | Method of drying biomass |
US9057037B2 (en) | 2010-04-20 | 2015-06-16 | River Basin Energy, Inc. | Post torrefaction biomass pelletization |
US9889225B2 (en) * | 2010-08-20 | 2018-02-13 | Kaohsiung Medical University | Method for bone formation by administering poly(lactic-co-glycolic acid) cross-linked alendronate |
TR201903835T4 (tr) * | 2010-12-06 | 2019-04-22 | Effrx Pharmaceuticals Sa | Hızlı çözünme özelliklerine sahip stabil efervesan bifosfonat formülasyonları. |
CN103070824B (zh) * | 2013-01-24 | 2014-07-16 | 天津红日药业股份有限公司 | 一种含有伊班膦酸钠的注射液 |
EP3054980B1 (en) * | 2013-10-08 | 2019-09-04 | InnoPharma, Inc. | Aprepitant oral liquid formulations |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1187828B (it) * | 1985-05-24 | 1987-12-23 | Gentili Ist Spa | Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi |
GB8618259D0 (en) * | 1986-07-25 | 1986-09-03 | Leo Pharm Prod Ltd | Pharmaceutical compositions |
DE3822650A1 (de) * | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US4922007A (en) * | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
FI83421C (fi) * | 1989-06-21 | 1991-07-10 | Huhtamaeki Oy | Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat. |
US5227506A (en) * | 1989-09-06 | 1993-07-13 | Merck & Co., Inc. | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors |
CA2035179C (en) * | 1990-01-31 | 2001-08-14 | Gerald S. Brenner | Pharmaceutical compositions containing insoluble salts of bisphosphonic acids |
US5356887A (en) * | 1990-01-31 | 1994-10-18 | Merck & Co., Inc. | Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids |
US5019651A (en) * | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
FR2703590B1 (fr) * | 1993-04-05 | 1995-06-30 | Sanofi Elf | Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse . |
-
1994
- 1994-05-17 US US08/245,289 patent/US5462932A/en not_active Expired - Lifetime
-
1995
- 1995-05-08 IL IL11365195A patent/IL113651A/xx not_active IP Right Cessation
- 1995-05-09 TW TW084104572A patent/TW402501B/zh not_active IP Right Cessation
- 1995-05-11 MY MYPI95001236A patent/MY112285A/en unknown
- 1995-05-12 DK DK95924570T patent/DK0759757T3/da active
- 1995-05-12 AU AU29010/95A patent/AU691634B2/en not_active Expired
- 1995-05-12 WO PCT/US1995/005926 patent/WO1995031203A1/en active IP Right Grant
- 1995-05-12 PL PL95320614A patent/PL179634B1/pl not_active IP Right Cessation
- 1995-05-12 UA UA96124659A patent/UA29505C2/uk unknown
- 1995-05-12 AT AT95924570T patent/ATE222495T1/de active
- 1995-05-12 CN CN95193086A patent/CN1079672C/zh not_active Expired - Fee Related
- 1995-05-12 RU RU96123917/14A patent/RU2176507C2/ru not_active IP Right Cessation
- 1995-05-12 NZ NZ289231A patent/NZ289231A/en unknown
- 1995-05-12 EP EP95924570A patent/EP0759757B1/en not_active Expired - Lifetime
- 1995-05-12 SI SI9530610T patent/SI0759757T1/xx unknown
- 1995-05-12 PT PT95924570T patent/PT759757E/pt unknown
- 1995-05-12 CZ CZ963367A patent/CZ285860B6/cs not_active IP Right Cessation
- 1995-05-12 JP JP52977395A patent/JP4111536B2/ja not_active Expired - Fee Related
- 1995-05-12 KR KR1019960706447A patent/KR100372966B1/ko not_active IP Right Cessation
- 1995-05-12 ES ES95924570T patent/ES2180646T3/es not_active Expired - Lifetime
- 1995-05-12 MX MX9605660A patent/MX9605660A/es unknown
- 1995-05-12 DE DE69527842T patent/DE69527842T2/de not_active Expired - Lifetime
- 1995-05-12 CA CA002190148A patent/CA2190148C/en not_active Expired - Fee Related
- 1995-05-12 SK SK1477-96A patent/SK281098B6/sk unknown
- 1995-05-12 HU HU9603162A patent/HU220626B1/hu not_active IP Right Cessation
- 1995-05-16 CO CO95020682A patent/CO4600739A1/es unknown
- 1995-05-16 DZ DZ950055A patent/DZ1884A1/fr active
- 1995-05-16 HR HR950293A patent/HRP950293B1/xx not_active IP Right Cessation
- 1995-05-16 ZA ZA953960A patent/ZA953960B/xx unknown
- 1995-05-17 YU YU31795A patent/YU49354B/sh unknown
-
1996
- 1996-11-15 NO NO19964864A patent/NO310179B1/no not_active IP Right Cessation
- 1996-11-15 FI FI964593A patent/FI118296B/fi not_active IP Right Cessation
-
1998
- 1998-08-12 HK HK98109860A patent/HK1009245A1/xx not_active IP Right Cessation
-
2003
- 2003-03-03 CY CY0300019A patent/CY2336B1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2180646T3 (es) | Formulaciones liquidas orales de alendronato. | |
RU95109905A (ru) | Композиции в жидком, полутвердом, твердом, гелеобразном или пастообразном виде и способ лечения заболеваний полости рта | |
NZ503946A (en) | Oral dosage form in an oval or caplet shape for administration of bisphosphonates and other known medicaments | |
HK1050313A1 (en) | Oral transmucosal drug dosage using solid solution | |
HUP0101017A2 (hu) | Készítmény és eljárás szájon át adagolható vakcinák és gyógyászati hatóanyagok szisztémás bevitelére | |
RU94027680A (ru) | Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы | |
ATE289199T1 (de) | Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten | |
WO1999040883A3 (en) | Compositions and methods for the treatment of cystic fibrosis | |
BR9802537A (pt) | Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração | |
IS7006A (is) | Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd | |
RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
EE04330B1 (et) | Levosimendani transmukoossed koostised ja nende kasutamine ravimi valmistamiseks | |
DE69531166D1 (de) | Arzneistoff zur erleichterung der durch immunsuppressiva verursachten nebenwirkungen | |
TW200517119A (en) | Method of treatment using interferon-tau | |
HUP0301408A2 (hu) | Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására | |
EG17992A (en) | Preparation of a medicament for arthritis and theumatism | |
RU98118897A (ru) | Способ увеличения массы костной ткани при переломах | |
RU98109932A (ru) | Применение 1-(2-нафт-2-илэтил)-4-(3-трифторметилфенил)-1,2,3,6-тетрагидропиридина для получения лекарственных средств, предназначенных для лечения бокового амиотрафического склероза |